Categories
Blood Cancer

BELINDA: Tisagenlecleucel in B-cell NHL [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Pediatric Cancer

Celebrating #HockeyFightsCancer Night [Video]

Thank you 5th Line for your continued support as we fight the good fight against pediatric cancer on #HockeyFightsCancer Night, pres. by Ohio Health.Follow the #CBJ on social media!Twitter: https://cbj.co/CBJTwitterInstagram: https://cbj.co/CBJIGFacebook: https://cbj.co/CBJFB